Science Angel Syndicate

It operates as a deal-by-deal syndicate rather than a pooled fund. Members choose which specific investments to participate in, avoiding the blind-pool commitment model. This structure sidesteps the standard management-fee-plus-carry waterfall, giving investors more direct control over their exposure. The trade-off is that the syndicate has no guaranteed capital reserve for follow-on investments, which can affect founders seeking committed multi-stage backing.

It focuses on pre-seed and seed-stage deep tech and life sciences companies, with a strong emphasis on university spinouts. Typical sectors include enterprise software, AI/ML, and digital health. The syndicate targets the funding gap between academic grants and institutional venture capital, where promising intellectual property often struggles to find commercial backing.

The syndicate's deal-by-deal model means individual investments can be as small as roughly £100,000, though this varies per opportunity. There is no publicly disclosed minimum commitment across a fund cycle, because no pooled fund exists. Investors evaluate each opportunity separately, which allows for a wide range of check sizes depending on the member's own capital allocation strategy.

Yes. The syndicate frequently co-invests alongside other angel networks, venture builders, and early-stage institutional funds, particularly for rounds emerging from UK research universities. This collaborative approach helps de-risk individual deals and provides founders with a broader network of expertise. It also allows the syndicate to participate in rounds that might otherwise exceed the capacity of its member base on a standalone basis.

Many of the syndicate's investments are structured to qualify for the UK's Seed Enterprise Investment Scheme (SEIS) or Enterprise Investment Scheme (EIS). These provide significant tax relief — up to 50% income tax relief for SEIS and 30% for EIS — alongside capital gains tax advantages and loss relief. The syndicate's concentration on early-stage UK qualifying companies aligns with the design of these schemes, making them a core part of the value proposition for UK-based angel investors.